Published in Hepatitis Weekly, November 13th, 2000
Preliminary research presented at the Annual Meeting of the American Association for the Study of Liver Diseases, held in Dallas, Texas, during October 2000, suggests that these patients can begin or continue treatment at full dosage and without interruption when also treated with the platelet growth factor Interleukin-11 (Oprelvekin, marketed under the brand name Neumega).
This first-of-its kind study, conducted at Georgetown University...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly